These highly selective human monoclonal antibodies restore and potentiate T-cell antitumor response by inhibiting the nexus of PD-1 on T cells and PD-L1 expression on tumor cells—the PD-1 blockade pathway (Hamid et al., 2013; Harvey, 2014; Menzies & Long, 2013). The gene discussed is PDCD1; the disease is neoplasm.